China's CanSino climbs on forecasting narrowing loss, higher FY revenue

Cansino Biologics

20/01/2025 04:54

** Hong Kong shares of CanSino Biologics Inc  6185.HK  climb
2.8% to HK$29, the highest since Jan. 7; on course for third
straight session of gains
    ** Clinical-stage vaccine company estimates its 2024 net
loss narrowing to 335-385 mln yuan ($45.80-$52.63 mln) range
from 1.48 bln yuan loss in 2023, with revenue amounting to
825-865 mln yuan range, as compared to 2023's 357.1 mln yuan
revenue
    ** "During the reporting period, the group mainly focused on
advancing commercialization of the meningococcal conjugate
vaccines and the development of non-COVID-19 vaccine candidates"
- CanSino
    ** Shanghai-listed stock  688185.SS  rises 2.4% to 58.78
yuan, highest since Jan. 7; set for the second session of rise
    ** In China, the blue-chip CSI 300 Index  .CSI300  gains
0.9% and the Shanghai Composite Index  .SSEC  adds 0.5%
    ** In Hong Kong, the healthcare index  .HSCIH  jumped 2.5%
and Hang Seng Index  .HSI  rises 2.3%
    ** Last year, CanSino's Hong Kong stock rose 33.8%, while
Shanghai shares fell 18.1% 

    ($1 = 7.3148 yuan) 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))